Malignancy - Factbites
 Factbites
 Where results make sense
About us   |   Why use us?   |   Reviews   |   PR   |   Contact us  

Topic: Malignancy


    Note: these results are not from the primary (high quality) database.


Related Topics

  
 Hematological malignancy - Wikipedia, the free encyclopedia
Hematological malignancies are the types of cancer that affect blood, bone marrow and lymph nodes.
Although hematological malignancies are a form of cancer, they are generally treated by specialists in hematology, although in many hospitals oncology specialists also manage these diseases.
As the three are intimately connected through the immune system, a disease affecting one of the three will often affect the others as well: although lymphoma is technically a disease of the lymph nodes, it often spreads to the bone marrow, affecting the blood and occasionally producing a paraprotein.
en.wikipedia.org /wiki/Hematological_malignancy   (404 words)

  
 Cancer - Wikipedia, the free encyclopedia
Biopsy and microscopical examination can also distinguish between malignancy and hyperplasia, which refers to tissue growth based on an excessive rate of cell division, leading to a larger than usual number of cells but with a normal orderly arrangement of cells within the tissue.
Hematological malignancies, such as leukemia and lymphoma, arise from blood and bone marrow.
A cancer may be suspected for a variety of reasons, but the definitive diagnosis of most malignancies must be confirmed by microscopic examination of the cancerous cells by a pathologist.
en.wikipedia.org /wiki/Cancer   (5818 words)

  
 Encyclopedia: Anemia
Although hematological malignancies are a form of cancer, they are generally treated by specialists in hematology, although in many hospitals oncology specialists also manage these diseases.
Acute lymphocytic leukaemia (ALL), also known as acute lymphoblastic leukaemia is a cancer of the white blood cells, characterised by the overproduction and continuous multiplication of malignant and immature white blood cells (referred to as lymphoblasts) in the bone marrow.
Leukemia (leukaemia in Commonwealth English) is a group of blood diseases characterized by malignancies (cancer) of the blood-forming tissues.
www.nationmaster.com /encyclopedia/Anemia   (4460 words)

  
 Hematological Malignancies, University of Minnesota Cancer Center
The hematological malignancy multidisciplinary program is actively engaged in both national and regional clinical trials for hematological malignant tumors.
Hematologic malignancies are cancers of the body's blood-forming and immune systems---the bone marrow and lymphatic tissues.
You may search the Cancer Center's clinical trial database to find a current list of trials for lymphoma, myeloma, and leukemia, or contact our program coordinators.
www.cancer.umn.edu /page/clinical/hemato.html   (1990 words)

  
 Molecular genetic biomarkers in hematological malignancies.
Most hematopoietic malignancies are widely disseminated even in their "early" stages and often do not have a well-defined localized phase.
Here, we outline the biological basis for the application of biomarkers for the early detection of hematological neoplasia.
Accordingly, these clinical settings might prove to be good models for evaluating molecular cancer risk markers and the possible introduction of chemoprevention.
www.aegis.com /aidsline/1997/jun/M9760506.html   (392 words)

  
 Genes at Work - Lab Testing
Chromosomal abnormalities in hematological malignancies are strongly correlated with tumor type and may play a role in earliest stages of tumor initiation.
In some chronic hematologic disorders, longer incubation or short term stimulation with PHA or other mitogen may be required.
In the clinical setting, cytogenetic analysis has proven to be an invaluable tool in the diagnosis, prognosis, and management of hematologic malignancies.
www.umdnj.edu /genesatwork/labtesting/27_nonrandom.html   (568 words)

  
 Aspergillus/Aspergillosis website
78 patients with hematological malignancies, 39 with inborn errors of metabolism, 3 with immunological deficiencies, and 2 patients with solid tumors.
This assay has been evaluated with serum mainly from patients receiving treatment for hematological malignancies and although the specificity of the LA-test was high, substantial variation in sensitivity was observed (Table 1) (1,6-12).
The LA-test was found positive in only 12% of serum samples from patients with hematological malignancies on the day the diagnosis of invasive pulmonary aspergillosis was made (20).
www.aspergillus.man.ac.uk /secure/diagnosis/verweij.html   (1870 words)

  
 Title page for etd-0909104-145326
The purposes of this study are to assay the VEGF activity and its correlation with disease prognosis in various hematological disorders; and to detect the VEGF autocrine activity of tumor cells in sequential culture without any stimulation in vitro.
In 17 Cases of malignant lymphoma, low D0 VEGF value (<300 pg) had good prognosis; those cases relapsed after treatment had high auto-secretary activity (high VEGF value of 7th culture day) and had bad disease prognosis, but there was no statistic significance.
Angiogenesis is not only essential for tumor growth but is also implicated in invasion of the cancer cells into the circulation, and growth of dormant micro-metastases into frank metastatic lesions.
etd.lib.nsysu.edu.tw /ETD-db/ETD-search/view_etd?URN=etd-0909104-145326   (407 words)

  
 Listeriosis in hematological malignancies: report of two cases.
Listeriosis occurred in two patients with hematological malignancies, one with adult T-cell leukemia (ATL) (Case 1) and the other with chronic granulocytic leukemia (CGL) (Case 2).
Listeriosis in hematological malignancies: report of two cases.
In Case 1, listeriosis was the initial manifestation of ATL, while it occurred in Case 2 after prolonged treatment with an alkylating agent and splenic irradiation.
www.aegis.com /aidsline/1989/sep/M8990458.html   (349 words)

  
 Multiple Myeloma Treatment - Multiple Myeloma symptoms.
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Multiple myeloma (MM) is one of several diseases that have been collectively termed "plasma cell dyscrasias" and accounts for 10% of all hematological malignancies.
The immune system is composed of several types of cells that work together to fight off infection and other disease.
clikngo.com /medical/HM008.HTM   (684 words)

  
 Expression in Hematological Malignancies of a Glucocorticoid Receptor Splice Variant That Augments Glucocorticoid Receptor-mediated Effects in Transfected Cells -- de Lange et al. 61 (10): 3937 -- Cancer Research
Genetic abnormalities of the GR are not a common cause of GC resistance in hematological malignancies.
Expression in Hematological Malignancies of a Glucocorticoid Receptor Splice Variant That Augments Glucocorticoid Receptor-mediated Effects in Transfected Cells -- de Lange et al.
The cause of GC resistance in hematological malignancies is
cancerres.aacrjournals.org /cgi/content/full/61/10/3937   (4122 words)

  
 UPCI 02-03 sci. rpt. hematological malignancies overview
The Hematological Malignancies Program of the University of Pittsburgh Cancer Institute investigates the mechanisms involved with the onset and progress of blood disorders, and also studies novel methods by which these processes can be altered.
Accordingly, much of the program's research is focused on the genetic and cellular origins of leukemia, lymphoma and myeloproliferative disorders, as well as the development of agents used in treating hematologic malignancies.
The program intends their work to ultimately produce innovative and effective treatment methods for combating blood cancers.
www.upci.upmc.edu /report/Clinical/hema   (143 words)

  
 The Epithelial Tumor Antigen MUC1 Is Expressed in Hematological Malignancies and Is Recognized by MUC1-specific Cytotoxic T-Lymphocytes -- Brossart et al. 61 (18): 6846 -- Cancer Research
The Epithelial Tumor Antigen MUC1 Is Expressed in Hematological Malignancies and Is Recognized by MUC1-specific Cytotoxic T-Lymphocytes -- Brossart et al.
The Epithelial Tumor Antigen MUC1 Is Expressed in Hematological Malignancies and Is Recognized by MUC1-specific Cytotoxic T-Lymphocytes
malignancies that could potentially be used for immunotherapeutic
cancerres.aacrjournals.org /cgi/content/abstract/61/18/6846   (843 words)

  
 Phase I Study of Oral Topotecan in Hematological Malignancies -- Beran et al. 9 (11): 4084 -- Clinical Cancer Research
Phase I Study of Oral Topotecan in Hematological Malignancies -- Beran et al.
(MTD) of oral topotecan in patients with hematological malignancies.
Phase I Study of Oral Topotecan in Hematological Malignancies
clincancerres.aacrjournals.org /cgi/content/abstract/9/11/4084   (355 words)

  
 A NOVEL VACCINE FOR HEMATOLOGICAL MALIGNANCIES USING DENDRITIC CELLS
Allogeneic stem cell transplantation has a significant contribution to the improved outcome of patients with hematological malignancies.
Such specific anti-leukemic donor CTLs may be utilized to maximize the anti-tumor effects of DLI in patients relapsing after allogeneic transplantation.
Nevertheless, a significant proportion of patients suffer from recurrence of the disease, which ultimately leads to death.
www.celltherapy.org /Abstracts2004/Abstracts/080.htm   (244 words)

  
 Stanford Cancer Center - Leukemia & Hematological Malignancies
We offer state-of-the-art chemotherapy protocols for leukemia and other hematologic malignancies, and Stanford hematologists have helped develop the National Comprehensive Cancer Network (NCCN) guidelines for the management of hematologic malignancies.
Patients with leukemia are evaluated and treated in Stanford's Hematology and Bone Marrow Transplant clinics by a team of world-renowned physicians.
Leukemia is cancer of the blood and develops in the bone marrow.
cancer.stanfordhospital.com /cancerTypes/leukemias   (799 words)

  
 FASEB 2001 Conference on Hematological Malignancies
The fact that they isolated this gene is a good indication that their analysis is accurate.

BCL-6 is known to repress transcription of the chemokine genes MIP-1 and IP-10, along with c-Myc and the cell cycle inhibitor p27kip1.

Resulting fluorescent intensities are collected using a laser confocal fluorescent microscope, and ratio information is used to compare expression levels for each gene between the 2 cell types.

This "expression profiling" is valuable for leukemia researchers, who hope to classify and subclassify the different hematological malignancies based on molecular data, rather than clinical information only.

Gene expression profiling of lymphoid malignancies reveals new cancer types and mechanisms of malignant transformation.
www.medscape.com /content/2001/00/40/84/408469/408469.xml   (3180 words)

  
 Mismatch repair deficiency in hematological malignancies with microsatellite instability
Using both biochemical and genetic approaches, this study analysed MMR proficiency in 11 cell lines derived from patients with hematological malignancies and demonstrated that six out of seven hematological cancer cell lines with MSI were defective in strand-specific MMR.
MSI has also been observed in hematological malignancies, but whether these hematological malignancies are associated with MMR deficiency is still unclear.
From these results, we conclude that, as in solid tumors, hematological malignancies with MSI are also associated with MMR deficiency, and that the cause of MMR deficiency in these cell lines is due to a defective MutS
www.nature.com /doifinder/10.1038/sj.onc.1205695   (326 words)

  
 Clinically Useful Information Provided by the Flow Cytometric Immunophenotyping of Hematological Malignancies: Current Status and Future Directions -- Orfao et al. 45 (10): 1708 -- Clinical Chemistry
Recent advances in flow cytometry: applications to the diagnosis of hematologic malignancy.
of hematological malignancies is not analyzed in depth.
Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia.
www.clinchem.org /cgi/content/full/45/10/1708   (6845 words)

  
 Radiological Imaging in Hematological Malignancies - Compare Shop Books
This is one of the first books to deal specifically with imaging of the entire spectrum of hematological malignancies.
The following chapters describe exhaustively the imaging features of hematological malignancies, supported by thorough radiological and histological illustrations and tables.
In the first chapter of the book, magnetic resonance imaging of the bone marrow is discussed in detail.
www.compareshopbooks.com /3540439994.htm   (272 words)

  
 Cancer Cell Biology
Researchers at the Institute for Molecular Medicine have found that multiple adhesive mechanisms are responsible for malignant cell adhesion to microvessel endothelial cells and to underlying subendothelial matrix, and they have begun to identify and isolate the receptors responsible.
Haier, J. and Nicolson, G.L. Hematological malignancies in cancer research.
For example, it was found that nerve growth factor can stimulate the invasion of brain-metastatic melanoma cells by increasing the synthesis of degradative enzymes.
www.immed.org /illness/cancer_cell_biology_research.html   (4324 words)

  
 Biochemical and Genetic Control of Apoptosis: Relevance to Normal Hematopoiesis and Hematological Malignancies -- Wickremasinghe and Hoffbrand 93 (11): 3587 -- Blood
The expression of BCL-2 by the malignant cells of ALL patients at presentation is highly variable.
malignant cells from the remaining 70% of patients undergo rapid
contributes to the accumulation of malignant cells in this disease.
www.bloodjournal.org /cgi/content/full/93/11/3587   (6618 words)

  
 ICML: Campath-1H and Rituximab for the Treatment of Hematological Malignancies
LUGANO, SWITZERLAND -- June 16, 2002 -- The combination of the monoclonal antibodies campath-1H and rituximab is safe and effective in patients with relapsed and/or refractory hematological malignancies, according to the results of an exploratory study.
ICML: Campath-1H and Rituximab for the Treatment of Hematological Malignancies
Title: ICML: Campath-1H and Rituximab for the Treatment of Hematological Malignancies
www.docguide.com /dg.nsf/PrintPrint/639CF59AC6B000E785256BDA00606D78   (550 words)

  
 Dendritic Cell-Based Vaccines in Patients with Hematological Malignancies -- BRUGGER et al. 938 (1): 359 -- Annals of the New York Academy of Sciences
Dendritic Cell-Based Vaccines in Patients with Hematological Malignancies -- BRUGGER et al.
Dendritic Cell-Based Vaccines in Patients with Hematological Malignancies
malignancies as well as on some B-cell lymphomas and multiple
www.annalsnyas.org /cgi/content/abstract/938/1/359   (217 words)

  
 Clinical Trial: STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients with Hematologic Malignancies
Male and female patient 18 years and older with histologically or cytologically confirmed hematological malignancy [other than acute myeloid leukemia (AML)and myelodysplastic syndrome (MDS)] and if treatment is medically indicated
The purpose of this study is to determine the safety, toxicity and patient tolerance of STA-5312 administered intravenously to patients with relapsed or refractory hematological malignancies.
Patients with CLL and other leukemic malignancies will be staged according to the modified Rai staging criteria
clinicaltrials.gov /ct/show/NCT00088101?order=1   (542 words)

  
 Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment -- Dimeo et al. 15 (8): 1237 -- Annals of Oncology
Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment -- Dimeo et al.
Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment
Background: Fatigue is a frequent and severe problem after treatment
annonc.oxfordjournals.org /cgi/content/abstract/15/8/1237   (272 words)

  
 brain breast cancer tumor
Examples include: bladder carcinoma, blood (and bone marrow)- hematological malignancies, leukemia, lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, brain tumor, breast cancer...
News Doxorubicin Mesathelioma Malignant Pleural Epithelioid Tumors Pain Chrysolite Breast Cancer Brain Tumor Malignant Diagnosis Asbesto Cisplatin Asco Cases Mine Michigan Attorneys Florida Cancer...
Osteosarcoma / Malignant Fibrous Histiocytoma Bone Marrow Transplantation Brain Tumor Breast...
brain-cancer.info /brainbreastcancertumor   (1108 words)

  
 Hematological Malignancies - Support & Understanding
When you or a loved one first hear the diagnosis of a hematological malignancy (blood cancer) such as leukemia or lymphoma, you may understandably feel anxious and unsure about the future.
However, many people find that learning about their condition can actually help relieve their fears and allow them to focus on maintaining their quality of life.
If you cannot find the information you need, you may wish to use our search facility
www.hemonc-usa.com   (239 words)

  
 PXD101 for Solid and Hematological Malignancies in Phase I
PXD101 appears to selectively target cancer cells and will be investigated for both solid and hematological malignancies
PXD101 for Solid and Hematological Malignancies in Phase I
www.curagen.com /presentation/pxd101/tsld004.htm   (51 words)

  
 Cellular immunotherapy of hematological malignancies
Hematologie > Research > Cellular immunotherapy of hematological malignancies
www.lumc.nl /4010/research/Cellular_immunotherapy.html   (174 words)

Try your search on: Qwika (all wikis)

Factbites
  About us   |   Why use us?   |   Reviews   |   Press   |   Contact us  
Copyright © 2005-2007 www.factbites.com Usage implies agreement with terms.